These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 14725792)

  • 21. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.
    Longva KE; Pedersen NM; Haslekås C; Stang E; Madshus IH
    Int J Cancer; 2005 Sep; 116(3):359-67. PubMed ID: 15800944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
    Friedländer E; Arndt-Jovin DJ; Nagy P; Jovin TM; Szöllosi J; Vereb G
    Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
    Kasuya K; Shimazu M; Suzuki M; Itoi T; Aoki T; Tsuchida A
    Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new therapeutic antibody masks ErbB2 to its partners.
    Badache A; Hynes NE
    Cancer Cell; 2004 Apr; 5(4):299-301. PubMed ID: 15093533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen.
    Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY
    Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu--a new method of epitope definition.
    Riemer AB; Kraml G; Scheiner O; Zielinski CC; Jensen-Jarolim E
    Mol Immunol; 2005 May; 42(9):1121-4. PubMed ID: 15829301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
    Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
    Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative binding analysis of monoclonal antibodies against native and mutant type in ErbB2 receptor: a theoretical modeling approach.
    Rajasekaran R; Rao S
    Curr Pharm Biotechnol; 2009 Nov; 10(7):701-8. PubMed ID: 19751177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes.
    Deng X; Zheng X; Yang H; Moreira JM; Brünner N; Christensen H
    PLoS One; 2014; 9(9):e106448. PubMed ID: 25192037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obtaining and characterization of monoclonal antibodies against recombinant extracellular domain of human epidermal growth factor receptor 2.
    Sarina N; Abeldenov S; Turgimbayeva A; Zhylkibayev A; Ramankulov Y; Khassenov B; Eskendirova S
    Hum Antibodies; 2018 Feb; 26(2):103-111. PubMed ID: 29036807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.
    Bostrom J; Yu SF; Kan D; Appleton BA; Lee CV; Billeci K; Man W; Peale F; Ross S; Wiesmann C; Fuh G
    Science; 2009 Mar; 323(5921):1610-4. PubMed ID: 19299620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
    Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
    Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.
    Spiridon CI; Ghetie MA; Uhr J; Marches R; Li JL; Shen GL; Vitetta ES
    Clin Cancer Res; 2002 Jun; 8(6):1720-30. PubMed ID: 12060609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
    Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
    Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.
    D'Avino C; Paciello R; Riccio G; Coppola C; Laccetti P; Maurea N; Raines RT; De Lorenzo C
    Protein Eng Des Sel; 2014 Mar; 27(3):83-8. PubMed ID: 24421342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro.
    Hosseini Ghatar R; Soltantoyeh T; Bahadori M; Khoshnoodi J; Golsaz Shirazi F; Jeddi Tehrani M; Amiri MM; Shokri F
    Iran J Immunol; 2017 Sep; 14(3):200-214. PubMed ID: 28919583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu.
    Riemer AB; Klinger M; Wagner S; Bernhaus A; Mazzucchelli L; Pehamberger H; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Immunol; 2004 Jul; 173(1):394-401. PubMed ID: 15210798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.
    zum Büschenfelde CM; Hermann C; Schmidt B; Peschel C; Bernhard H
    Cancer Res; 2002 Apr; 62(8):2244-7. PubMed ID: 11956077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
    Xia W; Gerard CM; Liu L; Baudson NM; Ory TL; Spector NL
    Oncogene; 2005 Sep; 24(41):6213-21. PubMed ID: 16091755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X; Wang S; Lee CK; Yang X; Liu B
    Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.